Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. This study investigates the role and mechanisms of ADAM9 as a biomarker and potential therapeutic target in HCC. Utilizing RNA-sequencing data and clinicopathological characteristics from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, we conducted survival and meta-analyses, functional enrichment, and immune infiltration studies. Additionally, we evaluated the effects of ADAM9 silencing on HCC cell proliferation, migration, and invasion through in vitro experiments. Our results demonstrate that high ADAM9 expression is associated with poor prognosis and increased immune infiltration in HCC patients. Furthermore, ADAM9 knockdown significantly inhibited tumor cell proliferation and migration. These findings indicate that ADAM9 is a promising prognostic biomarker and potential therapeutic target in HCC. In conclusion, ADAM9 could offer avenues for developing strategies to inhibit tumor progression and improve patient outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531474 | PMC |
| http://dx.doi.org/10.1038/s41598-024-74650-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antitumor Effects of Doxorubicin-Loaded Cellulose Nanoparticles in the Rabbit VX2 Liver Tumor Model.
Cardiovasc Intervent Radiol
September 2025
Department of Radiology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea.
Purpose: To evaluate the preclinical efficacy and safety of transarterial chemoembolization (TACE) using doxorubicin-loaded biocompatible cellulose nanoparticles in a rabbit VX2 liver tumor model.
Materials And Methods: Following institutional animal care committee approval, 23 rabbits with VX2 liver tumors were randomized into three groups: Group A (n = 9) received doxorubicin-loaded cellulose nanoparticles with ethiodized oil; Group B (n = 9) received doxorubicin with ethiodized oil; and Group C (n = 5) served as untreated controls. Tumor size was monitored via ultrasound for 4 weeks, and serum liver enzymes (aspartate transaminase and alanine transaminase) were measured on days 1, 3, and 7 to assess hepatotoxicity.
Comparison of Diagnostic Accuracies of Radiomics and Non-radiomics Model for Preoperative Prediction of Macrotrabecular-Massive Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
Acad Radiol
September 2025
Department of Radiology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Electronic address:
Rationale And Objectives: The diagnostic value of traditional imaging methods and radiomics in predicting macrotrabecular-massive hepatocellular carcinoma (MTM HCC) is yet to be ascertained. Therefore, this meta-analysis aims to compare the diagnostic performance of radiomics and conventional imaging techniques for MTM HCC.
Materials And Methods: Comprehensive publications were searched in PubMed, Embase, Web of Science, and Cochrane Library up to 28 February 2025.
vtRNA1-1 drives regorafenib resistance by sustaining cancer stemness via impaired autophagy and altered svRNA biogenesis.
Int J Biol Macromol
September 2025
Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No.100 Haining Road, Shanghai, 200080, PR China; Shanghai Eye Diseases Prevention &Treatment Center/Shanghai Eye Hospital, School of Medicine, Tongji University, PR China. Electronic address
While vault RNA1-1 (vtRNA1-1) has been implicated in tumor biology, its specific role in cancer stemness and regorafenib resistance remains unexplored. In this study, we identify vtRNA1-1 as a critical regulator of cancer stemness and chemoresistance in Hepatocellular carcinoma (HCC). vtRNA1-1 enhances stemness properties by modulating the nuclear accumulation of Nanog, a core transcription factor.
View Article and Find Full Text PDFHigh-throughput screening identifies a dual-activity inhibitor of OXCT1 for hepatocellular carcinoma therapy.
Bioorg Chem
September 2025
State Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Science and Medicine, University of Science and Technology of China, Hefei 230027, China; Institute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei 230601, China;
3-Oxoacid CoA-transferase 1 (OXCT1) plays a crucial role in hepatocellular carcinoma (HCC) progression through its ketolytic and succinyltransferase activities. Despite its potential as a therapeutic target, no small molecules have been developed to inhibit the dual enzymatic activities of OXCT1 specifically. In this study, our structural analysis revealed that the active sites for both enzymatic functions of OXCT1 are located in the same pocket.
View Article and Find Full Text PDFMechanisms of C5ORF13 in promoting epithelial-mesenchymal transition in hepatocellular carcinoma via eIF6 and the intervention of valproic acid.
Pathol Res Pract
September 2025
Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing 400030, China. Electronic address:
Objective: To investigate the mechanism by which C5ORF13 promotes epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma (HCC) through interaction with eukaryotic translation initiation factor 6 (eIF6) and its clinical significance, and to identify the potential use of valproic acid (VPA) as an eIF6 inhibitor in HCC.
Methods: The expression of C5ORF13 in HCC and its prognostic impact were analyzed using GEPIA, UALCAN, and The HUMAN PROTEIN ATLAS databases. Lentiviral transfection technology was used to knock down or overexpress C5ORF13 and eIF6.